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Human papillomavirus (HPV) is a major aetiological agent in anal carcinomas. We here present a study of global gene expression
using microarray hybridisation in a collection of anal carcinoma biopsies. Quantitative PCR was used to verify expression of selected
genes. All biopsies contained integrated DNA of human papillomavirus subtype 16 (HPV16) and expressed HPV16 E7 mRNA. No
other subspecies of HPV were detected in these 13 biopsies as assessed by PCR amplification and DNA sequencing. Unsupervised
cluster analysis, based on global mRNA expression, divided the tumour biopsies into two distinct groups. Cluster analysis based on a
number of high-risk HPV and/or E2F-regulated genes reproduced this biopsy grouping, suggesting that integrated HPV16 substantially
influenced global gene expression in approximately half the biopsies studied. The levels of HPV16 E7 mRNA were significantly
different between the two groups, but with considerable overlap. Thus, influence on global gene expression could not be absolutely
ascribed to the expression level of HPV16. To investigate whether this distinction in gene expression had prognostic impact, we
studied protein expression in an independent cohort of 55 anal carcinomas not included in the microarray study of two differentially
expressed candidate genes, minichromosome maintenance complex component 7 (MCM7) and cyclin-dependent kinase inhibitor
2A (CDKN2A or p16). HPV status was assessed by in situ hybridisation. There was a significant association between in situ staining for
HPV E7 mRNA and immunostaining for CDKN2A (p16) and MCM7 protein. CDKN2A (p16) mRNA was found significantly
differentially expressed between the two tumour groups. However, cluster analysis on genes directly regulated by CDKN2A (p16)
could not reproduce this split of biopsies into two groups, suggesting that the transcriptional regulatory activity of CDKN2A in these
biopsies is inhibited. Furthermore, protein expression of CDKN2A (p16) could not be associated with survival. MCM7 is directly
regulated by E2F and induced by HPV, and its mRNA was found differentially expressed between the two tumour groups. High level
of MCM7 protein was found to be associated with both improved relapse-free survival (RFS, P¼0.02) and cancer-specific survival
(CSS, P¼0.03) in anal cancer patients treated with radiation with or without additional chemotherapy.
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It is widely accepted that the aetiological agent of the large
majority of anal squamous cell carcinomas (SCCs) is the human
papillomavirus (HPV) (zur Hausen, 1989; Frisch et al, 1997;
Goedert et al, 1998; Daling et al, 2004). Other mechanisms, such as
immunosuppression, dramatically increase the risk for developing
anal cancer (Penn, 1986; Arends et al, 1997). The HPV family
comprises numerous epitheliotropic subtypes affecting the skin,
the oropharyngeal or the anogenital mucosa. Some mucosal HPV
subtypes, mainly human papillomavirus subtype 16 (HPV16) and
human papillomavirus subtype 18 (HPV18), are considered high
risk for neoplastic development (Munoz et al, 2003) and express
the viral oncogenes E6 and E7 with transforming properties (zur
Hausen, 2000). The transforming potential of E6 and E7 are, at
least in part, based on their inactivation of both p53 by the E6
protein (Werness et al, 1990) and the retinoblastoma (RB1) protein
by E7 (Dyson et al, 1989) leading to genomic instability,
inadequate G1/S checkpoint control and antiapoptosis. The
oncogenic potential of high-risk HPV is probably activated by
the integration of viral genome into the host cell genome. When
this integration leads to disruption of the HPV E2 gene, it results in
elevated expression of E6 and E7 and, consequently, enhanced
degradation of the host cell tumour repressor proteins p53 and
RB1 (Alani and Munger, 1998; Psyrri et al, 2004). In addition, cells
that express E6/E7 from integrated HPV sequences have a selective
growth advantage over cells with episomal HPV genomes (Jeon
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set al, 1995). The concept that loss of E2 repressor function may be
critical for malignant progression is supported by experiments
showing that re-expression of E2 in cervical cancer cell lines causes
growth suppression (Thierry and Yaniv, 1987). Other factors,
including sequence variants of HPV subtypes, seem to be
important for the oncogenic potential of the virus (Fujinaga
et al, 1994; Ellis et al, 1995; Hecht et al, 1995).
The retinoblastoma protein (pRB) pathway plays a central role
in regulating the progression through the G1 phase of the
mammalian cell cycle (Sherr, 1996). The core members of this
pathway include, in addition to pRB (and its family members p107
and p130), the D-type cyclins that, in association with CDK4 and
CDK6, promote proliferation of the cell cycle and the INK4 family
of cyclin-dependent kinase inhibitors (including cyclin-dependent
kinase inhibitor 2A (CDKN2A) or p16) that specifically binds and
inhibits the activity of CDK4 and CDK6. Also, the most studied and
the best-understood targets for pRB are members of the E2F
transcription factor family (Dyson, 1998; Muller et al, 2001). The
transcription factor E2F is a key transcriptional regulator
belonging to a family of transcription factors responsible for
transcriptional control of genes encoding proteins involved in
several biological processes (Cobrinik, 2005). This includes DNA
replication, enzymes involved in deoxynucleotide biosynthesis,
proteins that assemble to form functional origin of replication
complexes, and kinases involved in the activation and initiation of
cell-cycle progression (Ishida et al, 2001) as well as transcription of
negative regulators of cell-cycle progression such as CDKN2C
(p18) (Blais et al, 2002). The high frequency of alterations that
have been identified in the pRB pathway in human cancer, a
pathway central for the regulation of cell proliferation, suggest that
the deregulation of the pRB pathway is an obligatory event in
human cancer (Hanahan and Weinberg, 2000).
Given the many HPV subtypes, and the transforming function
being dependent on sequence variants and integration events,
establishing the oncogenic potential in a given HPV-infected
cancer is a complex task. Rather than identifying the exact viral
species or variant, we propose that it will be advantageous to
investigate the effects of the integrated virus on global gene
expression, thus possibly establishing potential markers that can
be associated with disease outcome. Although HPV is strongly
associated with anal cancer (Daling et al, 2004), it is not known
how the presence of high-risk HPV affects global gene expression
in anal cancer in vivo. To elucidate potential prognostic or
predictive markers for HPV-associated anal cancer, we analysed
the mRNA expression profile in 13 HPV16-positive anal cancer
biopsies and 4 HPV16-negative normal anal mucosa samples.
Furthermore, we tested the associations between protein expres-
sion of two isolated target genes, MCM7 and CDKN2A (p16) with
HPV E7 mRNA expression and with the clinical outcome in 55 anal
cancer patients.
MATERIALS AND METHODS
Patient and tissue samples
Microarray expression analysis The biopsies used for gene
expression analyses were taken from 13 patients with anal
carcinoma, prior to treatment, and are summarised in Table 1.
One sample was obtained at the University Hospital of Tromsø
(Tromsø, Norway). The rest of the samples were obtained at
Haukeland University Hospital (Bergen, Norway). Eleven of these
patients were women. The mean age was 66.3 years (range: 45–88
years). The histology was SCC in all, except for one case with
Paget’s disease (ca-29), and one had a basaloid type of SCC (ca-36).
The TNM stage for each patient is given in Table 1. All patients
except ca-20 and ca-47 were treated with radiation therapy
combined with concomitant chemotherapy using mitomycin C
(10mgm
 2) and 5-fluorouracil (1000mgm
 2, days 1–4). Patient
ca-20 was a 63-year-old woman presenting with T4N2 disease, and
patient ca-47 was a 54-year-old man with T3N1 disease and a
possible retroperitoneal lymph node metastasis (M1). These two
had first two courses of chemotherapy with 5-fluorouracil and
cisplatin (80mgm
 2) with 3 weeks interval, and then they were
given concomitant chemotherapy with cisplatin (60mgm
 2) and
5-fluorouracil during the first week of radiation therapy. Primary
surgery was not performed in the 13 patients. The mean follow-up
was 40 months (range: 25–58 months for patients alive).
Three patients had a relapse (as indicated in Table 1) and died
from anal carcinoma. Patient ca-41 had a distant relapse 52
months from diagnosis and died 3 months later. Patient ca-24 had
a local relapse at 11 months and died 1 month later, while patient
ca-47 (with possible M1 disease initially) died from distant
metastases 31 months after diagnosis. Among the 10 nonrelapsing
patients, two have experienced breast cancer during follow-up
(patients ca-22 and ca-39).
Fresh tissue samples were taken with a conchotome, directly
snap-frozen in liquid nitrogen and stored at  801C. All biopsy
specimens were examined by a histopathologist and classified
according to WHO criteria (Hermanek, 1992). Clinical data were
collected from the hospital files. Cytological smears obtained from
the biopsies immediately prior to tissue lysis and RNA extraction
were evaluated for the presence of tumour cells.
Tissue microarray Independent samples of formalin-fixed and
paraffin-embedded (FFPE) tumour tissues from the time of
diagnosis, prior to therapy, from 62 patients with anal carcinoma
Table 1 The histopathological diagnosis, group (based on gene expression), TNM stage and relapse status
Biopsy no. Histology Group
a TNM stage, age and sex
b Relapse
c (months) Status
d (months)
ca-3 SCC I T2N0M0, 54, M No Alive (49)
ca-20 SCC I T4N2M0, 63, F No Alive (34)
ca-23 SCC I T3N0M0, 45, M No Alive (37)
ca-29 Paget I T3N0M0, 88, F No Alive (58)
ca-36 SCC, basaloid I T3N2M0, 75, F No Alive (25)
ca-39 SCC I T2N0M0, 78, M No Alive (54)
ca-11 SCC II T3N2M0, 62, F No Alive (50)
ca-22 SCC II T2N0M0, 56, F No Alive (47)
ca-24 SCC II T4N2M0, 80, F Yes, LR (11) Dead (12)
ca-25 SCC II T2N0M0, 48, F No Alive (38)
ca-34 SCC II T4N3M0, 78, F No Alive (37)
ca-41 SCC II T3N0M0, 81, F Yes, DR (52) Dead (55)
ca-47 SCC II T3N3M1, 47, M M1 at diagnosis Dead (6)
F¼female; M¼male; SCC¼squamous cell carcinoma; TNM¼tumour, nodes and metastases.
aGroup according to unsupervised hierarchical cluster analysis.
bTNM stage
according to 1987 revision. Age at diagnosis.
cLR¼local relapse; DR¼distant relapse; M1¼distant metastases at diagnosis.
dClinical status with time interval from diagnosis.
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swere selected from a previous patient cohort. A tissue
microarray (TMA) was performed as described below. Seven of
them were treated with surgery alone. The 55 patients included in
the survival analyses were treated with radiation alone or
combined with concomitant chemotherapy (5-fluorouracil
(1000mgm
 2 days 1–4) and mitomycin C (10mgm
 2)( n¼30);
UKCCCR ACTWP, 1996; Bartelink et al, 1997). Among these 55
patients, the median radiation dose was 50Gy (range: 28–60Gy).
Of 46 patients treated with concomitant chemotherapy, 28
received one course and 18 patients received two courses of
chemotherapy.
Mean follow-up time was 7.2 years.
RNA extraction
Total RNA was extracted using the Qiagen RNeasy minikit
(QIAGEN GmbH, Hilden, Germany), as recommended by the
manufacturer. The first flow-through fraction was collected for
subsequent DNA extraction. Three micrograms of total RNA was
subjected to DNase I treatment to remove any contaminating
genomic DNA, using TURBO DNaset (Ambion, cat. no. 2238). The
RNA quality and quantity were evaluated by Agilent Bioanalyzer
and OD260-280, respectively.
DNA extraction
Genomic DNA was extracted from the first flow-through following
the RNA purification protocol. Briefly, 350ml flow-through were
mixed with 1ml linear acrylamide (Ambion, cat. no. 9520) and
500ml 100% EtOH, vortexed and centrifuged at 13000g in a
tabletop centrifuge. The precipitate was air-dried, and subse-
quently purified by Qiagen DNA minikit (cat. no. 13323).
Detection of genomic human papillomavirus DNA
Quantification of HPV16 and 18 DNA was done as described
(Lamarcq et al, 2002). All samples were run in triplicate.
Estimation of the relative copy number of HPV16 or HPV18
DNA was performed by the comparative CT method relative to the
peripheral myelin protein 22 gene (pmp22). In addition, sub-
species of HPVs were assessed by PCR amplification with
degenerate PCR primers (MY09 and MY11) (Manos et al, 1989)
followed by DNA sequencing (data not shown).
Microarray
Gene expression analysis was performed on the ABI 1700
Expression array system (ABI, Foster City, CA, USA) with the
Applied Biosystems Chemiluminescent RT-IVT Labelling Kit (cat.
no. PN 4339629) and Human Genome microarray (ABI, cat. no.
4337467) using 2mg high-quality total RNA. Fifteen micrograms of
mRNAs were hybridised to the ABI microarray. The Applied
Biosystems Human Genome Survey Microarray v. 1.0 provides
31700 probes for interrogation of 27868 genes. Each probe is
a synthetic oligodeoxynucleotide of 60 nucleotides (nt).
The oligonucleotide probes are modified at the 30 end by the
addition of a C-6 spacer and are covalently attached to the support
via a terminal amino group. In almost all cases, probes
are placed within 1500nt of the 30 end, where labelling is
more robust. The Applied Biosystems 1700 Chemiluminescent
Microarray Analyzer is a component of the integrated Applied
Biosystems Expression Array System, which uses the power and
sensitivity of chemiluminescence to identify and measure gene
expression levels.
All procedures were performed according to the manufacturer’s
recommendations.
Analysis of microarray data
J-Express Pro v. 2.7 (Dysvik and Jonassen, 2001) was used for all
filtering, clustering and statistical analysis of the microarray
experiments. The compiled set consisted of 22385 individual
probes. Euclidean hierarchical clustering with average linkage
(weighted pair group method with arithmetic mean, WPGMA) was
performed on this data set for the total unsupervised clustering.
This unsupervised clustering divided the tumour biopsies into two
distinct clusters, group 1 (Gr1) and group 2 (Gr2). Biopsies
belonging to Gr1 were labelled in blue and in Gr2 labelled in red
and are consistently illustrated so throughout this paper. Addi-
tional filtering left 8449 spots remaining. All further analysis was
done on this set. To isolate the genes accounting for the observed
clustering, we grouped the biopsies according to the result of the
unsupervised cluster analysis and performed supervised T-test and
significance of microarray (SAM) (Tusher et al, 2001) analysis of
the two groups (Gr1 and Gr2), in both cases returning 500 probes
with the lowest P-value. The resulting 500 probes from the T-test
analysis were sorted according to the biological process classifica-
tion by the Human protein reference database (HPRD) (http://
www.hprd.org/). Of the 500 probes, 344 returned a unique HPRD
reference, the rest being either duplicate probes or hypothetical
genes that had no reference in this particular database. The HPRD
classification divided the 344 probes into eight distinct biological
processes. Euclidean hierarchical clustering with average linkage
was performed for each of the eight subgroups.
Quantitative real-time PCR analysis
Sequence-specific primers and TaqMan probes for HPV16 and
HPV18 E7 mRNA and DNA were used as described by others
(Lamarcq et al, 2002). For verification of microarray results with
real-time MGB Quantitative PCR, we used the following Applied
Biosystems AssayOnDemand probes: CHAF1B, chromatin
assembly factor 1, subunit B (p60) (Assay ID Hs00601414_m1);
MCM7, minichromosome maintenance complex component 7
(Hs00428518_m1); MSH6, mutS homolog 6 (Escherichia coli)
(Hs00264721_m1); PSIP1, PC4 and SFRS1 interacting protein 1
(Hs00253515_m1); KIF2C, kinesin family member 2C
(Hs00199232_m1); LMNB1, lamin B1 (Hs00194369_m1); LMNB2,
lamin B2 (Hs00383326_m1); MAPKAPK3, MAP kinase-activated
protein kinase 3 (Hs00177957_m1); GAS7, growth arrest-specific 7
(Hs00245902_m1); CCNB1, cyclin B1 (Hs00259126_m1); CCNA2,
cyclin A2 (Hs00153138_m1); CCNB2, cyclin B2 (Hs00270424_m1);
CDKN2C, cyclin-dependent kinase inhibitor 2C (p18)
(Hs00176227_m1); MDK, midkine (neurite growth-promoting
factor 2) (Hs00171064_m1); BNIPL, BCL2/adenovirus E1B 19kD
interacting protein like (Hs00370514_m1); and Bax, BCL2-asso-
ciated X protein (Hs00180269_m1). Statistical comparisons were
performed using the Mann–Whitney rank sum test with the
GraphPad Prist v. 4.0 software (GraphPad Software Inc., San
Diego, CA, USA). P-values were two-sided and considered
significant when o0.05.
Tissue microarray
Sixty-two formalin-fixed, paraffin-embedded tumour samples of
representative tumour regions from individual patients were used
for the preparation of a tumour TMA block. The TMA block was
constructed using a Manual Tissue Arrayer 1 (Beecher Instru-
ments, Silver Spring, MD, USA) with a 1.0-mm diameter core
biopsy needle. A pathologist reviewed the H&E-stained slides to
control for tissue quality and confirm the diagnosis. Following the
construction of the array block, 5mm sections were cut with a
microtome. Each slide used for immunohistochemistry (IHC) was
de-paraffinised and rehydrated following standard protocols.
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sImmunohistochemistry For the detection of MCM7 protein,
target retrieval was performed in 0.05% citraconic anhydride
solution, pH 7.4 (Namimatsu et al, 2005) at 1211C for 15min.
Immunohistochemistry was performed using an MCM7-specific
monoclonal antibody (47DC141, cat. no. ab2360; Abcam plc,
Cambridge, UK) diluted 1:200 in Antibody Diluent solution (cat.
no. S0809, Dako Denmark, Glostrup, Denmark). For the detection
system, the Polymer-HRP IHC Ready-to-Use Detection System/
DAB kit (no. QD400, Biogenex, San Ramon, CA, USA) was
used according to the manufacturer’s recommendations. Finally,
colour was developed using 3,30-diaminobenzidine (DAB;
Dako) and counterstained with haematoxylin (Dako; ChemMatet
Hematoxylin no. S-2020).
For the detection of CDKN2A (p16) protein, target retrieval was
performed in 10mM citrate-buffer pH 6 in a microwave oven.
Immunohistochemistry was performed using a CDKN2A (p16)-
specific antibody (BD Biosciences, Sparks, MD, USA, P/N 554070)
diluted 1:200 in Antigen Diluent Solution, using a Dako
Autostainer and the EnVision DAB detection system (Dako, P/N
K5007).
The sections were dehydrated and mounted using Eukitt
s
quick-hardening mounting medium (Fluka, Industriestrasse,
Buchs, Switzerland, cat. no. 03989).
Immunohistochemical analysis of p16 and MCM7 expression
was scored independently by two of the authors. The staining
intensity of MCM7 was categorised as negative (0), weak (1),
moderate (2) or strong (3). An index was made from the product of
staining intensity (0–3) and from the percentage of positive
tumour cells (0–100). This index then was categorised as low
(index o140, n¼27) or high (index X140, n¼28). The cutoff
value of 140 was the median value of the complete data set,
dividing the tumour biopsies essentially into two equal numbered
groups. The impact of the protein-staining index on clinical
outcome then was assessed on the 55 patients treated with
radiation with or without additional chemotherapy (that is the 7
patients treated with surgery alone were left out). The Kaplan–
Meier method (Bland and Altman, 1998) was used to estimate
relapse-free survival (RFS) and cancer-specific survival (CSS), and
the log-rank method was used to compare survival between
groups.
In situ hybridisation
The HPV in situ hybridisation (ISH) was performed using reagents
and INFORM
s HPV III Family 16 DNA Probe (B) (P/N 800-4295)
provided by Ventana Medical Systems Inc. (Tucson, AZ, USA).
Developed to stain FFPE tissue sections, this probe is designed to
detect HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and
66. This probe was used in conjunction with a Discovery
automated slide stainer, the RiboMap kit (P/N 760-102) and
BlueMap-detection kit (P/N 760-120), using a streptavidin alkaline
phosphatase conjugate that gives a blue colour in the chromogenic
reaction with NBP (nitroblue terazolium) and BCIP (5-bromo-4-
chloro-indolyl-phosphate). The 5-mm-thick sections were de-
paraffinised and rehydrated on the stainer. DNA unmasking was
performed with RiboCC buffer (P/N 760-107) and protease 3 (P/N
760-2020) for 20min. A mix of 200ml HPV III probe, 75ml
RiboHybe (P/N 760-104) and 25ml2   SSC was applied on each
slide for hybridisation. The probe and target were denatured at
951C for 8min and incubated for 2h at 521C for hybridisation.
Stringent wash were performed in 2  SSC at 721C. A 20-min
incubation with a rabbit anti-DNP antibody (P/N 780-4335) was
included prior to the 20-min incubation with the Universal
Secondary Antibody (P/N 760-4205). The slides were counter-
stained with ISH Red Counterstain (P/N 780-2186), dehydrated
through graded alcohols and xylene, and mounted. HPV-positive
cervix tumour was used as a positive control. A negative control,
omitting the probe, was included.
For HPV-ISH, nucleolar E7 mRNA was scored as negative, weak,
moderate, strong or intense by two independent investigators.
For analysis of association between MCM7 protein staining and
E7 mRNA, E7 mRNA was recoded as negative or positive, and
analysed by w
2 statistics including all 62 patients.
The Regional Ethics Committee Region West approved this
study.
RESULTS
Patient characteristics
Histopathological evaluation of the biopsies used for RNA
extraction is described in Table 1. Biopsies on the tissue array
included 62 patients with histologically confirmed primary anal
SCC.
Identification of HPV virus and evaluation of HPV16 viral
load
All cancer biopsies included in the microarray study tested
positive for HPV16 mRNA by quantitative real-time PCR analysis
(Figure 1), while the four normal mucosa biopsies tested negative.
No other subspecies of HPV virus were detected in this selection of
biopsies when performing PCR amplification with the degenerate
primers followed by DNA sequencing. The relative amount of
HPV16 E7 mRNA was higher in Gr2 compared with Gr1 (P¼0.05).
In two biopsies, ca-29 (Gr1) and ca-24 (Gr2), only small amounts
of HPV E7 mRNA were detected. For two of the biopsies (ca-3 in
Gr1 and ca-11 in Gr2), we were unable to isolate genomic DNA. For
the rest of the biopsies, the relative amount of viral DNA was
estimated by comparison to the single-copy gene, pmp22. The
estimated copy number of HPV16 genomes compared with host
cell genome varied from approximately six copies per cell to one
copy per 20 cells (HPV16 genome: host cell genome) (Figure 1).
Microarray analysis
Unsupervised hierarchical clustering on 22385 genes readily
distinguished tumours from the normal anal mucosa, and further
identified two main subclasses of anal carcinomas based on
distinct patterns of gene expression (Figure 3Aa). Further filtering,
eliminating genes not differentially regulated between the samples,
reduced the total number of probes to 8449. When performing a
SAM analysis (Tusher et al, 2001) on this set, comparing the
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Figure 1 Taqman quantitative PCR for Gr1 and Gr2 anal cancer biopsies
of the relative amounts of HPV16 E7 DNA relative to the single-copy gene
pmp22 (P¼0.12) and mRNA relative to b-actin mRNA (P¼0.05).
Gene expression in HPV16-positive anal carcinomas
O Bruland et al
1267
British Journal of Cancer (2008) 98(7), 1264–1273 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sRegulation of nucleic acid  metabolism
Cell growth and/or maintenance
Transport
Metabolism/energy  pathways
Apoptosis
Biological process unknown
Protein metabolism
N
T
8
N
T
1
1
c
a
-
3
9
N
T
9
N
T
1
0
c
a
-
3
c
a
-
3
6
c
a
-
2
9
c
a
-
2
0
c
a
-
2
3
c
a
-
1
1
c
a
-
2
4
c
a
-
2
5
c
a
-
3
4
c
a
-
2
2
c
a
-
4
1
c
a
-
4
7
N
T
8
N
T
1
1
N
T
9
N
T
1
0
c
a
-
3
c
a
-
3
6
c
a
-
2
9
c
a
-
2
0
c
a
-
2
3
c
a
-
3
9
c
a
-
1
1
c
a
-
3
4
c
a
-
2
2
c
a
-
2
4
c
a
-
2
5
c
a
-
4
1
c
a
-
4
7
N
T
8
N
T
9
N
T
1
0
N
T
1
1
c
a
-
3
9
c
a
-
3
c
a
-
3
6
c
a
-
2
9
c
a
-
2
0
c
a
-
2
3
c
a
-
1
1
c
a
-
3
4
c
a
-
2
2
c
a
-
2
4
c
a
-
2
5
c
a
-
4
1
c
a
-
4
7
N
T
8
N
T
1
1
c
a
-
3
9
N
T
9
N
T
1
0
c
a
-
3
c
a
-
3
6
c
a
-
2
0
c
a
-
2
3
c
a
-
2
9
c
a
-
1
1
c
a
-
3
4
c
a
-
2
2
c
a
-
2
4
c
a
-
2
5
c
a
-
4
1
c
a
-
4
7
N
T
8
N
T
9
N
T
1
0
N
T
1
1
c
a
-
3
9
c
a
-
3
c
a
-
2
0
c
a
-
2
9
c
a
-
2
3
c
a
-
3
6
c
a
-
1
1
c
a
-
3
4
c
a
-
2
2
c
a
-
2
4
c
a
-
2
5
c
a
-
4
1
c
a
-
4
7
N
T
8
c
a
-
3
9
N
T
9
N
T
1
0
N
T
1
1
c
a
-
3
c
a
-
2
9
c
a
-
2
0
c
a
-
3
6
c
a
-
2
3
c
a
-
1
1
c
a
-
3
4
c
a
-
2
5
c
a
-
4
1
c
a
-
2
2
c
a
-
4
7
c
a
-
2
4
N
T
8
c
a
-
3
6
c
a
-
3
c
a
-
2
0
c
a
-
2
3
c
a
-
2
9
N
T
9
N
T
1
1
N
T
1
0
c
a
-
3
9
c
a
-
1
1
c
a
-
2
2
c
a
-
3
4
c
a
-
2
4
c
a
-
4
7
c
a
-
2
5
c
a
-
4
1
N
T
8
N
T
1
1
N
T
9
N
T
1
0
c
a
-
3
9
c
a
-
3
c
a
-
2
9
c
a
-
3
6
c
a
-
2
0
c
a
-
2
3
c
a
-
1
1
c
a
-
3
4
c
a
-
2
2
c
a
-
2
4
c
a
-
4
7
c
a
-
2
5
c
a
-
4
1
0.0 Min Max
N
T
8
N
T
1
1
c
a
-
3
9
N
T
9
N
T
1
0
c
a
-
3
c
a
-
2
9
c
a
-
3
6
c
a
-
2
0
c
a
-
2
3
c
a
-
1
1
c
a
-
3
4
c
a
-
2
2
c
a
-
2
4
c
a
-
2
5
c
a
-
4
1
c
a
-
4
7 RFC3
H2AFZ
RNASEH2A
MCM8
FEN1
RAD51
MCM2
MCM7
TIMELESS
HMGB2
DNMT1
MSH6
H2AFV
FA NCG
POLQ
SMC4L1
TOP2A
FOXC1
ELL2
EXOSC2
MCM6
PSIP1
HNRPH3
CDK2
LMNB1
OK/SW-cl.56
BAZ1B
LMNB2
CENPF
KIF2C
TPX2
KIF23
SPAG5
ASK
DSG2
CLTB
EPB41L3
MYRIP
DSC1
CDSN
EVPL
LEP5
SPRR4
CDKN3
CDC2
CKS1B
CCNB2
KPNA2
CCNA2
BIRC5
SMC1L1
TOPBP1
PKMYT1
CDKN2C
DLG7
AURKB
STK6
CCNB1
KNTC2
TOP2A
MDK
LATS1
DUSP1
MYT1
ERK8
ASC
PTK6
RAB38
RAB5A
GAS7
ERBB2
MAPKAPK3
MAP2K4
WFDC5
CPA4
PRSS3
KLK6
MPN
HSPD1
RNF130
ADPRT
UBE2C
HMGCR
SMPD2
ACP5
ME1
PLCD1
HPSE
HMOX1
GPX6
GPX3
DGAT2
AGXT
ALDH4A1
DUT
SOD1
GMPS
HPRT1
NOD9
JMY
BNIP3L
BNIP3
PDCD6IP
IL17RC
Spc25
GTSE1
BCL2A1
AQP5
ABCA12
CLIC3
GJB6
GJB2
SLC28A3
ABCG4
VAMP1
HIG1
CNOT10
ANKRD9
RAI16
RPIP8
PGBD5
CDCA5
FKSG14
PLSCR1
MGC5576
C9orf76
DKFZP434B168
ANKRD25
LR8
ZD52F10
D4S234E
IL18
Unsupervised hierarchical clustering
Signal transduction/cell communication
ae
f
g
h
b
c
d
Figure 2 (A) Hierarchical clustering of all 337 genes selected by performing a T-test between the two tumour groups. (B) Distribution of 337 genes into
eight different biological processes, as defined by the Human Protein Reference Database (HPRD) (Ba–Bh). A heat map of the corresponding hierarchical
clustering illustrates the relation between all biopsies in each individual subgroup. The locations in each individual cluster of a number of selected genes are
indicated. The colour scale indicates the range of relative expression levels, red representing upregulated and green representing downregulated expression,
both as compared to the reference. See online version for colour figure.
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snormal tissue group with the tumour group, 1296 probes showed a
difference in expression level of more than twofold. Comparison of
the two tumour groups resulted in 2420 probes with expression
levels differing more than twofold. In all, 344 individual genes were
identified by performing a T-test between the two groups, followed
by annotation according to the HPRD and subsequent division
into eight groups depending on biological functions (Figure 2).
Euclidean hierarchical clustering was performed for the 344 genes
as a whole (Figure 2A), and subsequently for each of the eight
subgroups (Figure 2B). The gene symbol and location in the cluster
of a subset of the 344 genes is illustrated in Figure 2B. Most
notable, genes encoding proteins involved in DNA replication,
DNA repair, DNA binding and key regulators of the cell cycle were
upregulated in Gr2, while genes involved in cell–cell adhesion,
desmosome formation and apoptosis as well as several protein
kinases and phosphatases, members of the Rho-Ras GTPase
families and structural proteins were downregulated. Among the
344 genes identified, several were regulated by the transcription
factor E2F. Therefore, we determined expression profiles on a
selection of 114 genes specifically regulated by E2F (Ishida et al,
2001) and subsequently performed hierarchical clustering. The
resulting hierarchical clustering (Figure 3Ad) was highly similar to
both the hierarchical clustering of our unsupervised analysis
(Figure 3Aa) and to the hierarchical clustering of genes selected by
performing two independent statistical analyses between the two
tumour groups (Figure 3Ab and Ac). Similarly, to investigate the
possible transcriptional influence of high-risk HPV, we performed
hierarchical cluster analysis on genes reported differentially
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Figure 3 (A) Hierarchical clustering of the unsupervised analysis on (Aa) the selection of 8449 probes, (Ab) the 337 individual genes defined by the T-
test, (Ac) the 363 individual genes defined by the SAM analysis together with collections of genes described by others relevant to our study and included
within the group of 8449 probes, (Ad) HPV16-induced gene expression (Alazawi et al, 2002), (Ae) HPV16 E6/E7-induced gene expression (Nees et al,
2001), (Af) HPV31-induced gene expression (Chang and Laimins, 2000), (Ag) Gene expression in SSC (Loercher et al, 2004), (Ah) E2F-regulated genes
(Ishida et al, 2001), (Ai) HPV16- and HPV18-induced gene expression (Santin et al, 2005) and, finally, (Aj) HPV18 E6/E7-induced gene expression (Garner-
Hamrick et al, 2004). (B) The total number of genes within each report cited. The numbers listed in parenthesis following the author are the total number
with matching probes located on the ABI microarray. The number inside the large circle is the number of genes with matching probes in the 8449 selection.
The number outside the big circle corresponds to genes with matching probes on the ABI chip but not included in the 8449 selection. (C) Hierarchical
cluster analysis based on (Ca) CDKN2A (p16) transcriptionally regulated genes and (Cb) E2F-regulated genes, as reported by Vernell et al, 2003.
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sexpressed in several systems related to high-risk HPV infection.
This included gene expression profiling of a mouse SCC model
(Loercher et al, 2004), effect on overall gene expression associated
with integration of HPV16 in cervix SCC (Alazawi et al, 2002), gene
expression profiling of primary HPV16- and HPV18-infected early
stage cervical cancer (Santin et al, 2005), effect of HPV18 E6 and E7
on global gene expression in an organotypic keratinocytes culture
system (Garner-Hamrick et al, 2004), effect of HPV16 E6 and/or E7
on global gene expression in differentiating cervical keratinocytes
(Nees et al, 2001) and, finally, effect of HPV31 on global gene
expression in normal human keratinocytes (Chang and Laimins,
2000). Again, the resulting hierarchical cluster (Figure 3Ae–Aj) was
practically identical compared to our unsupervised analysis (Figure
3Aa). Figure 3B illustrates the number of genes reported by others
and used in this study as supporting information, and the
distribution of these genes within our selection.
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Figure 4 (A) Taqman analysis of 16 individual genes assessed relative to b-actin confirming the results from the microarray analysis. For all plots, the
median values of each group are indicated, with all values adjusted so that the median of the NT group equals 1. Each plot is identified by the corresponding
gene symbol of the target gene. P-values were two-sided and considered significant when o0.05. (B) Relative expression of the four cyclin-dependent
kinase inhibitors CDKN2-A-D, assessed by microarray hybridisation. The values are adjusted so that the median of the NT groups is equal to 1.
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sTo test whether this division into two groups was particular to
our collection of biopsies, we tested the mRNA expression of a
number of genes listed in Figure 2B in a new series of anal
carcinoma biopsies from six individual patients. The transcription
of these genes in these biopsies also divided them into two groups
with three biopsies in each group (data not shown).
Finally, we investigated expression profiling of genes selectively
regulated by either CDKN2A (p16) or by E2F as reported by
Vernell et al (2003). We found that hierarchical clustering based on
CDKN2A (p16)-regulated genes could not reproduce the unsu-
pervised clustering (Figure 3Ca), while genes regulated directly by
E2F reproduced the unsupervised cluster analysis (Figure 3Cb).
Quantitative real-time PCR analyses confirmed the results from
the microarray analysis for a selection of these genes (Figure 4).
Immunohistochemistry and tissue microarray
Following the results from the microarray analysis, CDKN2A (p16)
and MCM7 were selected as a typical gene overexpressed in Gr2
to be investigated in an independent cohort of 55 anal cancer
biopsies. CDKN2A (p16) protein staining was not significantly
related to survival in Kaplan–Meier analyses (log-rank test,
P¼0.70) (data not shown). However, we found that high
expression of MCM7 in this cohort of anal carcinomas correlated
with favourable clinical outcome (log-rank test, P¼0.017 for
probability of RFS and P¼0.011 for probability of CSS), as
illustrated in Figure 5Bb.
In situ hybridisation and HPV detection
Out of 62 cases with available representative tumour tissue, E7
mRNA was detected in 34 anal carcinoma biopsies (55%). The
intensity of the nucleolar staining was recorded as negative in 28
(45%), weak in 12 (19%), moderate in 8 (13%), strong in 8 (13%)
and intense in 6 (10%). There was a significant association between
E7 mRNA signal detected by ISH and MCM7 protein staining
detected by IHC. Out of 62 anal carcinoma patients, 33.3% of those
with a low MCM7 staining intensity (product o140) were HPV
positive, as compared with 68.4% of those with a high MCM7
product (P¼0.007, w
2 statistics). Also, there was a significant trend
for increasing MCM7 immunostaining with increasing E7 mRNA
staining intensity (recorded 0–4) (P¼0.007 w
2 test for trend). In
addition, there was a significant association between presence of
HPV mRNA and high CDKN2A (p16) immunostaining (P¼0.001).
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Figure 5 Immunohistochemical staining of MCM7 and CDKN2A proteins and ISH of HPV E7 mRNA is shown in (A), (Aa) MCM7 with predominant
nuclear staining, (Ab) CDKN2A with nuclear and cytosolic staining and (Ac) ISH showing staining of predominantly nucleolar HPV E7 mRNA. (B)
Immunohistochemical analysis of MCM7 protein expression in an anal carcinoma biopsy, illustrating one biopsy categorised as ‘high’ (upper pictures) (Ba)
and one biopsy categorised as ‘low’ (lower pictures) (Bb) in the following Kaplan–Meier analysis. Kaplan–Meier estimates of RFS (upper graph) (Bc) and
CSS (lower graph) (Bd) according to MCM7 protein expression among 55 patients with anal carcinomas.
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with an improved CSS in 55 anal carcinoma patients treated with
radiation with or without chemotherapy (Figure 5), presence of
HPV mRNA assessed by ISH was not significantly related to
survival in Kaplan–Meier analyses (log-rank test P¼0.92).
DISCUSSION
To our knowledge, this is the first description of how high-risk
HPV infection influences in vivo global gene expression patterns in
anal cancer. However, the effect of high-risk HPV on global gene
expression has been studied and characterised in several model
systems on different microarray platforms (Chang and Laimins,
2000; Nees et al, 2001; Alazawi et al, 2002; Vernell et al, 2003;
Garner-Hamrick et al, 2004; Loercher et al, 2004; Santin et al,
2005). Several biomarkers predicting both HPV status and
response to treatment for several cancers have been proposed.
MCM7 and CDKN2A (p16) were proposed as biomarkers for HPV-
positive head and neck cancer (Strati et al, 2006), while CDKN2A
(p16) alone was suggested as a marker in HPV-infected
oropharyngeal cancers with favourable prognosis (Weinberger
et al, 2006). MCM7 was also proposed as an informative biomarker
in cervical cancer (Brake et al, 2003). Both MCM7 and CDKN2A
(p16) are among a number of genes regulated by the transcription
factor E2F, and should therefore be transcriptionally induced in
cells infected by high-risk HPV.
By investigating gene expression profiles in anal cancer biopsies,
we identified two major subsets of anal cancers with unique and
distinct molecular fingerprints. All cancer biopsies included in the
microarray series tested positive for the presence of HPV16 mRNA
by quantitative PCR. No other species of HPV was detected by
PCR amplification followed by DNA sequencing in these particular
biopsies. This does not reflect the distribution of HPV in
Norwegian tumour samples reported by others, although HPV16
is reported to be the most common high-risk HPV in Norwegian
specimens, accounting for more than 50% of all cases (Kraus et al,
2004; Molden et al, 2005). Owing to the technical limitation of the
PCR/sequencing assay, we neither can exclude the presence of
other subspecies of HPV within our samples, nor can we exclude
the presence of viral variants, sequence disruptions or very low
HPV levels that escaped detection by the methods used.
Cyclin-dependent kinase inhibitor 2A (p16) and MCM7 were
significantly upregulated in one of the tumour subsets, indicating
that this subset (Gr2) could be characterised by E2F-regulated
transcription. This distinction could not be ascribed solely to the
presence of HPV16, as there were extensive variations in both the
relative amount of genomic viral DNA present and the level of viral
mRNA expressed. However, the distinction could be explained by a
major impact in penetrance of transcriptional regulation specifi-
cally controlled by E6 and E7, two of the genes encoded for by the
HPV16 genome. Furthermore, one of the two subsets (Gr2) could
be characterised by transcriptional regulation of many genes
involved in biological processes similar to those controlled by E2F.
Among the genes highly upregulated in Gr2, we identified several
proteins involved in the initiation of DNA replication, as MCM2,
MCM6, MCM7 and MCM8 (Figure 2), and three of the four cyclin-
dependent kinase inhibitors, namely, CDKN2A (p16), CDKN2C
(p18) and CDKN2D (p19) (Figure 4B).
To further characterise differences in the transcriptional
response in the two tumour groups, we isolated genes transcrip-
tionally controlled by CDKN2A (p16). However, cluster analysis
based on these genes could not reproduce the unsupervised
clustering (Figure 3C). This indicates that, although CDKN2A were
highly upregulated in Gr 2, the effect of CDKN2A protein on gene
expression does not follow the mRNA expression pattern of the
cyclin-dependent kinase inhibitors.
Analysis of the association between MCM7 and CDKN2A (p16)
protein expression, as accessed by IHC, and prognosis were
performed on a separate cohort of anal carcinomas consisting of
biopsies from 55 patients arranged in a tissue array. Human
papillomavirus statuses of these biopsies were assessed by ISH. We
found a strong correlation between high-risk HPV E7 staining and
both CDKN2A (p16) and MCM7 expression, but no association
between HPV expression and survival. This could, however, be due
to sensitivity limitations of the HPV assay. On the other hand,
elevated protein levels of MCM7 were significantly associated with
favourable prognosis in patients treated with concomitant radia-
tion and chemotherapy, both regarding RFS and CSS.
Our results suggest that transcriptional control exercised by the
cyclin-dependent kinase inhibitor CDKN2A is inhibited in anal
carcinomas. We also find that there is no association between
CDKN2A protein expression and probability for survival. Further-
more, we find no correlation between HPV expression and
survival, probably due to the limitations of the HPV assay, both
regarding sensitivity and the fact that it cannot detect variants of
HPV. We did, however, find a strong correlation between the
MCM7 gene product (E2F regulated, HPV induced and absolute
required for DNA replication) and both CSS and RFS. These
findings may have clinical implications.
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